Antiviral Effects of Human Placenta Hydrolysate (Laennec®) Against SARS-CoV-2 In Vitro and in the Ferret Model

    October 2021 in “ The Journal of Microbiology ”
    Eun-Ha Kim, Young‐Il Kim, Seung‐Gyu Jang, Minju Im, Kyeongsoo Jeong, Young Ki Choi, Hae-Jung Han
    Image of study
    TLDR Human placenta hydrolysate may help treat COVID-19 by reducing virus replication and boosting immune response.
    The study investigated the antiviral effects of human placenta hydrolysate (hPH) against SARS-CoV-2, comparing it to Remdesivir. In vitro tests showed that hPH inhibited virus replication in a dose-dependent manner. In a ferret model, hPH treatment led to minimal bodyweight loss and reduced virus replication in the respiratory tract. Additionally, hPH upregulated the expression of immune-related cytokines, specifically type I and II interferons. These findings suggested that hPH had potential as a therapeutic agent for treating SARS-CoV-2 infection.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results